Trending...
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Leading PDR Training Courses in Canada: Learn Paintless Dent Repair with PDR Academy & Tint Academy
- Merger Advancement For Embodied AI Co in Robotic Systems Serving High Value Hospitality, Gaming & Real Estate Sectors: MBody AI Corp. (NAS DAQ: MBAI)
FAYETTEVILLE, Ark. - PennZone -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on The PennZone
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on The PennZone
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
- Slotozilla Reports Strong Growth in Q2 2026
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
- Flexible Plan Investments Names Carl Resnick President
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
Source: Lineus Medical
0 Comments
Latest on The PennZone
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
- San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
- Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
- GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
- Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
- Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
- Colonial Nissan Earns Capital One Top Performing Dealership Award
- BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
- Logistics Expert Asks A Question Biology Has Overlooked: How Evolution Assembles Coordinated Novelty
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
- Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
- Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World
- DuraFast Label Company Launches Seiko SLP850 2" Thermal Printer with Free Label Promotion
- Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
- Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
- Philly Tailgates Announces Full 2026 Eagles Season Schedule, Opening With Back-to-back Events
